Short answer

Teleflex Inc (TFX) filed its fiscal 2012 10-K annual report with the SEC on Feb 22, 2013.

Top risk flagged: Healthcare Reform Act: 2.3% medical-device excise tax, estimated annual impact of approximately $15.0 million

Teleflex Inc FY2012 10-K analysis

AI summary of each section, grounded in the filing text

Global single-use medical technology provider, selling through direct sales and distributors in over 140 countries
20 new products and line extensions introduced during 2012
LMA acquisition and four late-stage technology acquisitions expanded anesthesia and technology capabilities
First year with four reportable segments, replacing single-segment reporting
Approximately 11,600 employees at December 31, 2012, including 8,500 outside the United States

Revenue $1,551.0M, up 3.9% YoY from $1,492.5M, despite $42.3M unfavorable currency impact
Gross margin 48.2% vs 47.5%; SG&A margin 29.3% vs 28.4%
Best segment: Asia revenue $173.7M, up 16.1%; worst: EMEA revenue $510.2M, down 2.9%
Operating cash flow $193.9M; capex $65.4M; acquisitions $387.0M; dividends $55.6M; no buybacks through December 31
Outlook: $15M annual medical-device excise tax from 2013; European receivables and austerity pose cash-flow risks

Healthcare Reform Act: 2.3% medical-device excise tax, estimated annual impact of approximately $15.0 million
European sovereign debt crisis: $101.0 million net receivables in Italy, Spain, Portugal and Greece
Manufacturing concentration: many key products rely on single facilities with limited alternate capacity
Competitive disruption: larger medical-device companies possess greater financial and marketing resources
Leverage: $970.0 million total consolidated indebtedness as of December 31, 2012

Generated from the filing text; verify against the original. How to read a 10-K

Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.